Method: Laboratory-developed test (LDT) validated under CLIA; not cleared or approved by the FDA. Results are interpreted by clinicians in context and are not a stand-alone diagnosis.

Methylmalonic acid (MMA) is a small organic acid that builds up when the body cannot properly use vitamin B12 (cobalamin).

Similar biomarker tests from Superpower

FAQs about Methylmalonic Acid Test

Methylmalonic acid (MMA) is a small organic compound made during normal breakdown of certain fats and proteins. Your cells need active vitamin B12 to convert MMA into a usable molecule that supports energy production. When B12 is deficient or not working properly at the cellular level, this conversion slows and MMA builds up in blood and urine. That’s why MMA is a sensitive marker of functional, tissue-level vitamin B12 deficiency.

Serum B12 shows how much B12 is circulating, but it doesn’t always reflect how well cells can use it. MMA testing measures the metabolic consequence of inadequate active B12 inside cells: MMA rises when B12-dependent metabolism stalls. This makes MMA especially helpful for spotting early or subtle B12 deficiency that can be missed by standard B12 blood tests, before anemia or severe neurological symptoms appear.

MMA testing can clarify whether symptoms like fatigue, tingling or numbness, brain fog, or memory lapses are linked to functional vitamin B12 deficiency. Because MMA can rise before anemia or major neurological findings, it helps flag early nerve damage risk while the condition is still treatable. It also supports more precise B12 supplementation decisions and can be used to track whether therapy is correcting the underlying metabolic problem.

Healthy MMA values are typically below about 0.4 micromoles per liter, indicating adequate B12 availability and efficient cellular metabolism. Being within the reference range generally suggests B12-dependent pathways supporting energy production, nerve insulation (myelin), red blood cell formation, and DNA synthesis are functioning. “Optimal” often means being at the lower end of the normal range, reflecting strong intracellular B12 activity and healthy mitochondrial metabolism.

High MMA most commonly indicates functional vitamin B12 deficiency - cells can’t process MMA because active B12 is insufficient. Early signs may include fatigue, numbness or tingling in hands/feet, balance problems, mood changes, and memory issues. If elevated MMA is left untreated, risk can increase for irreversible nerve damage, cognitive decline, and anemia. MMA is an early-warning marker that can rise before severe symptoms become obvious.

Yes. MMA is cleared through the kidneys, so reduced kidney function can raise MMA even without a primary B12 problem. Interpretation should consider estimated glomerular filtration rate (eGFR), age-related kidney changes, and overall clinical context. If MMA is high, evaluating kidney function helps distinguish impaired clearance from true functional B12 deficiency. This is one reason MMA results are often interpreted alongside other markers rather than in isolation.

MMA reflects whether vitamin B12 is actually working inside cells to complete a key metabolic reaction. Serum B12 can appear “normal” even when intracellular B12 activity is inadequate. When B12-dependent metabolism slows, MMA accumulates - making it a more specific indicator of functional deficiency at the cellular level. This specificity is valuable for identifying early deficiency affecting mitochondria, nerve function, and red blood cell production before damage becomes severe.

MMA provides a view of B12 function in cells; serum B12 shows circulating levels; and homocysteine adds context about methylation-related metabolism. Interpreting MMA alongside serum B12 and homocysteine can improve detection of early or borderline deficiency, especially when symptoms suggest B12 issues but a standard B12 test is inconclusive. This combined approach supports a more complete picture of metabolic health, neurological risk, and long-term system-wide effects.

If MMA is elevated due to functional B12 deficiency, effective B12 therapy should help restore the B12-dependent pathway and lower MMA over time. Monitoring MMA can confirm that supplementation is correcting the metabolic bottleneck, not just raising serum B12 numbers. This can be useful when symptoms persist, when initial B12 labs were borderline, or when absorption issues are suspected, helping guide more targeted treatment decisions.

A common misconception is that “normal serum B12 means no deficiency.” MMA can still be high when cells can’t use B12 effectively. Frequent causes include poor B12 absorption (low stomach acid, certain medications, pernicious anemia), strict vegan diets without supplementation, and age-related changes. Kidney dysfunction can also elevate MMA due to reduced clearance. Rarely, inherited enzyme defects in MMA processing can raise levels, so context matters when interpreting results.